astragaloside a has been researched along with transforming growth factor beta in 16 studies
| Studies (astragaloside a) | Trials (astragaloside a) | Recent Studies (post-2010) (astragaloside a) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 675 | 5 | 573 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 6 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, QC; Zhang, YK; Zhu, TY | 1 |
| Li, SJ; Yang, YZ; Zhang, ZC | 1 |
| Chen, L; Chen, X; Gao, JQ; Li, N; Liang, WQ; Peng, LH | 1 |
| Dong, N; Huang, LF; Li, JF; Li, WX; Sheng, ZY; Yao, YM; Yu, Y; Zhang, SW | 1 |
| Gu, L; Mou, S; Ni, Z; Qi, C; Shao, X; Wang, Q; Xu, W | 1 |
| Cai, H; Chi, YF; Peng, W; Wang, L; Yin, PH; Yuan, ZT; Zhang, XM; Zhou, WC | 1 |
| Cha, X; Li, D; Mao, Y; Qi, Q; Yi, J; Zhu, K | 1 |
| Bi, ZG; Chen, B; Chen, G; Ji, C; Jiang, HL; Li, R; Qian, W; Yan, N | 1 |
| Dong, H; Guo, H; Liang, Y; Niu, Y; Wang, X | 1 |
| Dong, S; Guan, Y; Wang, L; Wang, Y; Wu, X; Yang, S; Zhao, Y | 1 |
| Feng, K; Tang, Y; Tao, R; Wei, Y; Wu, Y; Xu, H; Zhao, Y | 1 |
| Guo, Y; Jin, Y; Li, L; Wei, J; Zhao, Y | 1 |
| Ping, S; Rongjia, Z; Xiaotong, Z; Xiuping, Y | 1 |
| Gao, Q; Li, Y; Pan, L; Zhang, X | 1 |
| Hu, G; Li, X; Li, Y; Shen, L; Song, X; Wang, X; Xu, X | 1 |
| Fang, JA; Hu, YL; Li, SF; Liu, WY; Liu, XJ; Zhang, ZY | 1 |
16 other study(ies) available for astragaloside a and transforming growth factor beta
| Article | Year |
|---|---|
[Effect of astrgaloside IV on the long-term consequences of renal ischemia-reperfusion injury in rat].
Topics: Animals; Down-Regulation; Drugs, Chinese Herbal; Kidney; Male; Nephrectomy; Phytotherapy; Random Allocation; Rats; Rats, Sprague-Dawley; Reperfusion Injury; RNA, Messenger; Saponins; Transforming Growth Factor beta; Triterpenes | 2004 |
[Effect of astragaloside on myocardial fibrosis in chronic myocarditis].
Topics: Animals; Blotting, Western; Chronic Disease; Coxsackievirus Infections; Drugs, Chinese Herbal; Endomyocardial Fibrosis; Male; Matrix Metalloproteinase 13; Matrix Metalloproteinase 14; Mice; Mice, Inbred BALB C; Myocarditis; Random Allocation; Saponins; Transforming Growth Factor beta; Triterpenes | 2007 |
Topical astragaloside IV-releasing hydrogel improves healing of skin wounds in vivo.
Topics: Administration, Topical; Alginates; Animals; Female; Gelatin; Glucuronic Acid; Hexuronic Acids; Hydrogels; Rats; Rats, Sprague-Dawley; Saponins; Skin; Tensile Strength; Transforming Growth Factor beta; Triterpenes; Wound Healing | 2012 |
The effect of Astragaloside IV on immune function of regulatory T cell mediated by high mobility group box 1 protein in vitro.
Topics: Animals; CD4 Antigens; Cell Proliferation; Cells, Cultured; Forkhead Transcription Factors; Gene Expression Regulation; HMGB1 Protein; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Male; Mice; Molecular Structure; RNA, Messenger; Saponins; Spleen; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Triterpenes | 2012 |
Astragalosides IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells.
Topics: Apoptosis; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Enzyme Activation; Epithelial Cells; Glucose; Hepatocyte Growth Factor; Humans; Kidney Tubules, Proximal; p38 Mitogen-Activated Protein Kinases; Saponins; Signal Transduction; Transforming Growth Factor beta; Triterpenes | 2014 |
Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro.
Topics: Animals; Disease Models, Animal; Fibrosis; Gene Expression Profiling; Kidney; Kidney Diseases; Kidney Function Tests; Rats, Sprague-Dawley; Saponins; Severity of Illness Index; Signal Transduction; Smad7 Protein; Transforming Growth Factor beta; Triterpenes | 2014 |
Anti-fibrotic effects of Astragaloside IV in systemic sclerosis.
Topics: Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Humans; Mice; RNA, Messenger; Saponins; Scleroderma, Systemic; Smad3 Protein; Transforming Growth Factor beta; Triterpenes | 2014 |
Astragaloside IV controls collagen reduction in photoaging skin by improving transforming growth factor-β/Smad signaling suppression and inhibiting matrix metalloproteinase-1.
Topics: Cell Line; Cell Survival; Collagen; Fibroblasts; Gene Expression Regulation; Humans; Matrix Metalloproteinase 1; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Saponins; Signal Transduction; Skin Aging; Smad Proteins; Transforming Growth Factor beta; Triterpenes; Ultraviolet Rays | 2015 |
Astragaloside IV synergizes with ferulic acid to suppress hepatic stellate cells activation in vitro.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Coumaric Acids; Drug Synergism; Hepatic Stellate Cells; Humans; In Vitro Techniques; NF-E2-Related Factor 2; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saponins; Transforming Growth Factor beta; Triterpenes | 2017 |
Astragaloside IV inhibits cell proliferation in vulvar squamous cell carcinoma through the TGF-β/Smad signaling pathway.
Topics: Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; G1 Phase Cell Cycle Checkpoints; Humans; Saponins; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Triterpenes; Vulvar Neoplasms | 2019 |
Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway.
Topics: Animals; Animals, Newborn; Astragalus Plant; Cardiomyopathy, Hypertrophic; Cells, Cultured; Disease Models, Animal; Fibrosis; Humans; Isoproterenol; Male; Medicine, Chinese Traditional; MicroRNAs; Myocardium; Myofibroblasts; Plant Extracts; Plant Roots; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Triterpenes; TRPM Cation Channels | 2020 |
Effect of astragaloside IV on cognitive dysfunction in rats with cerebrally infarcted via TGF-β / Smad signaling pathway.
Topics: Animals; Case-Control Studies; Cerebral Infarction; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Rats; Rats, Sprague-Dawley; Saponins; Severity of Illness Index; Signal Transduction; Smad Proteins; Smad1 Protein; Smad3 Protein; Smad7 Protein; Transforming Growth Factor beta; Triterpenes | 2020 |
Effect of astragaloside IV on the immunoregulatory function of adipose-derived mesenchymal stem cells from patients with psoriasis vulgaris.
Topics: Adipose Tissue; B7-H1 Antigen; Cell Differentiation; Cells, Cultured; Humans; Mesenchymal Stem Cells; Osteogenesis; Psoriasis; Saponins; Transforming Growth Factor beta; Triterpenes; Tumor Necrosis Factor-alpha | 2022 |
Astragaloside IV attenuates high glucose-induced human keratinocytes injury via TGF-β/Smad signaling pathway.
Topics: Glucose; Humans; Inflammation; Keratinocytes; Signal Transduction; Transforming Growth Factor beta | 2022 |
Astragaloside IV suppresses the migration and EMT progression of cervical cancer cells by inhibiting macrophage M2 polarization through TGFβ/Smad2/3 signaling.
Topics: Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Humans; Interleukin-10; Macrophages; Smad2 Protein; Transforming Growth Factor beta; Uterine Cervical Neoplasms | 2023 |
[Effects of astragaloside IV on delaying kidney aging and its mechanisms].
Topics: Aging; Animals; bcl-2-Associated X Protein; Interleukin-6; Kidney; Male; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; RNA, Messenger; Saline Solution; Sirtuin 1; Transforming Growth Factor beta; Tumor Suppressor Protein p53; Urea | 2022 |